ITGAM and neoplasm: Since we observed reduction in CCL2 levels in both the tumor and sera of CD11b-modulated tumors (i.e., GB1275 treated and CD11b KI), we hypothesized that reduced CCL2 in the blood may result in reduced levels of circulating Ly6Chi monocytes.